Knowridge1 天
How an existing drug could help ease lower back pain
Lower back pain is a common issue that affects around 8 out of 10 people at some point in their lives. Researchers are now ...
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in ...
Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be ...
FDA Has Recalled Thousands of Bottles of Antidepressant Duloxetine, Sold Under Brand Name ...
The Duloxetine Delayed-Release Capsules' voluntary recall began on Oct. 10 after the FDA deemed the medication the ...
New Atlas3 天
"Bizarre" way ant venom hits a nerve: An exciting new path to pain relief
Insect venom may seem like an unlikely ally in the discovery of new human pain treatments, but the latest findings into the ...
Thousands of bottles of common antidepressant Cymbalta recalled by FDA over cancer-causing ...
Thousands of bottles of a commonly prescribed antidepressant drug were recalled because they contained a suspected cancer-causing chemical.
FDA recalls 7,000 bottles of antidepressant due to cancer-causing chemical
Thousands of bottles of an antidepressant have been recalled by the U.S. Food and Drug Administration due to a cancerous ...
MIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatments
MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...
Antidepressant recalled: 2nd-highest FDA risk level; drug contains cancerous chemical
The U.S. Food and Drug Administration updated the risk level of a recalled antidepressant due to the product containing high ...
ophthalmologytimes5 天
First patient dosed in clinical trial to treat neuropathic corneal pain
According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic ...
phillyvoice.com10 天
Physical therapy can address the root causes of chronic pain
In 2020, an estimated 54 million adults in the U.S. were living with chronic pain. Over 25 percent of them were treating ...
Duloxetine Antidepressant Recall Update As FDA Sets Risk Class
On October 11, the recall was classified as a class II recall by the FDA—a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health ...